联合免疫疗法与血管内皮生长因子拮抗剂治疗肝细胞癌：向前迈进的一步 - Suppr

Combined immunotherapy and VEGF-antagonist in hepatocellular carcinoma: a step forward.

作者信息

Bhoori Sherrie, Mazzaferro Vincenzo

机构信息

Hepatology, Hepato-pancreato-biliary Surgery and Liver Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Department of Oncology, University of Milan, Milan 20133, Italy.

出版信息

Lancet Oncol. 2020 Jun;21(6):740-741. doi: 10.1016/S1470-2045(20)30211-4.

DOI:10.1016/S1470-2045(20)30211-4

PMID:32502436

Abstract

摘要

相似文献

Combined immunotherapy and VEGF-antagonist in hepatocellular carcinoma: a step forward.

Lancet Oncol. 2020 Jun;21(6):740-741. doi: 10.1016/S1470-2045(20)30211-4.

Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.

J Hepatol. 2008 Jul;49(1):52-60. doi: 10.1016/j.jhep.2008.02.022. Epub 2008 Apr 28.

[Antiangiogenic therapy for gastrointestinal tumors].

Orv Hetil. 2008 Dec 7;149(49):2317-24. doi: 10.1556/OH.2008.28496.

Atezolizumab and Bevacizumab in Hepatocellular Carcinoma.

N Engl J Med. 2020 Aug 13;383(7):693-694. doi: 10.1056/NEJMc2021840.

Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.

BioDrugs. 2009;23(5):289-304. doi: 10.2165/11317600-000000000-00000.

Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. Reply.

N Engl J Med. 2020 Aug 13;383(7):695. doi: 10.1056/NEJMc2021840.

Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.

Lancet Oncol. 2020 Sep;21(9):e412. doi: 10.1016/S1470-2045(20)30430-7.

Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma - Authors' replys.

Lancet Oncol. 2020 Sep;21(9):e413. doi: 10.1016/S1470-2045(20)30476-9.

Atezolizumab and Bevacizumab in Hepatocellular Carcinoma.

N Engl J Med. 2020 Aug 13;383(7):694-695. doi: 10.1056/NEJMc2021840.

Atezolizumab and Bevacizumab in Hepatocellular Carcinoma.

N Engl J Med. 2020 Aug 13;383(7):694. doi: 10.1056/NEJMc2021840.

引用本文的文献

ElF5B as a prognostic biomarker and its correlation with infiltrating immune cells in liver cancer.

Genes Genomics. 2025 Aug 25. doi: 10.1007/s13258-025-01671-6.

Global perspectives and hotspots of VEGF signaling pathway in liver disease from 2008 to 2023: A bibliometric analysis and visualization.

Heliyon. 2024 Dec 19;11(1):e41346. doi: 10.1016/j.heliyon.2024.e41346. eCollection 2025 Jan 15.

Comprehensive analysis of CXCL10 and MIP-3a reveals their potential clinical application in hepatocellular carcinoma.

Transl Oncol. 2024 Oct;48:102071. doi: 10.1016/j.tranon.2024.102071. Epub 2024 Aug 3.

Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment.

Mol Cancer. 2023 Feb 21;22(1):38. doi: 10.1186/s12943-023-01748-4.

Recent Perspectives on the Mechanism of Recurrence After Ablation of Hepatocellular Carcinoma: A Mini-Review.

Front Oncol. 2022 Aug 23;12:895678. doi: 10.3389/fonc.2022.895678. eCollection 2022.

SHR6390 Combined with Cabozantinib Inhibits Tumor Progression in the Hepatocellular Carcinoma Mouse Model.

Curr Gene Ther. 2024;24(5):453-464. doi: 10.2174/1566523222666220825110147.

Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis.

Front Oncol. 2022 Jun 23;12:877434. doi: 10.3389/fonc.2022.877434. eCollection 2022.

Drug delivery strategy in hepatocellular carcinoma therapy.

Cell Commun Signal. 2022 Mar 5;20(1):26. doi: 10.1186/s12964-021-00796-x.

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges.

Front Oncol. 2021 Oct 22;11:737497. doi: 10.3389/fonc.2021.737497. eCollection 2021.

Apatinib suppresses the migration, invasion and angiogenesis of hepatocellular carcinoma cells by blocking VEGF and PI3K/AKT signaling pathways.

Mol Med Rep. 2021 Jun;23(6). doi: 10.3892/mmr.2021.12068. Epub 2021 Apr 13.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Combined immunotherapy and VEGF-antagonist in hepatocellular carcinoma: a step forward.

作者信息

Bhoori Sherrie, Mazzaferro Vincenzo

机构信息

Hepatology, Hepato-pancreato-biliary Surgery and Liver Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Department of Oncology, University of Milan, Milan 20133, Italy.

出版信息

Lancet Oncol. 2020 Jun;21(6):740-741. doi: 10.1016/S1470-2045(20)30211-4.

DOI:10.1016/S1470-2045(20)30211-4

PMID:32502436

Abstract

摘要

相似文献

Combined immunotherapy and VEGF-antagonist in hepatocellular carcinoma: a step forward.

Lancet Oncol. 2020 Jun;21(6):740-741. doi: 10.1016/S1470-2045(20)30211-4.

Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.

J Hepatol. 2008 Jul;49(1):52-60. doi: 10.1016/j.jhep.2008.02.022. Epub 2008 Apr 28.

[Antiangiogenic therapy for gastrointestinal tumors].

Orv Hetil. 2008 Dec 7;149(49):2317-24. doi: 10.1556/OH.2008.28496.

Atezolizumab and Bevacizumab in Hepatocellular Carcinoma.

N Engl J Med. 2020 Aug 13;383(7):693-694. doi: 10.1056/NEJMc2021840.

Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.

BioDrugs. 2009;23(5):289-304. doi: 10.2165/11317600-000000000-00000.

Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. Reply.

N Engl J Med. 2020 Aug 13;383(7):695. doi: 10.1056/NEJMc2021840.

Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.

Lancet Oncol. 2020 Sep;21(9):e412. doi: 10.1016/S1470-2045(20)30430-7.

Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma - Authors' replys.

Lancet Oncol. 2020 Sep;21(9):e413. doi: 10.1016/S1470-2045(20)30476-9.

Atezolizumab and Bevacizumab in Hepatocellular Carcinoma.

N Engl J Med. 2020 Aug 13;383(7):694-695. doi: 10.1056/NEJMc2021840.

Atezolizumab and Bevacizumab in Hepatocellular Carcinoma.

N Engl J Med. 2020 Aug 13;383(7):694. doi: 10.1056/NEJMc2021840.

引用本文的文献

ElF5B as a prognostic biomarker and its correlation with infiltrating immune cells in liver cancer.

Genes Genomics. 2025 Aug 25. doi: 10.1007/s13258-025-01671-6.

Global perspectives and hotspots of VEGF signaling pathway in liver disease from 2008 to 2023: A bibliometric analysis and visualization.

Heliyon. 2024 Dec 19;11(1):e41346. doi: 10.1016/j.heliyon.2024.e41346. eCollection 2025 Jan 15.

Comprehensive analysis of CXCL10 and MIP-3a reveals their potential clinical application in hepatocellular carcinoma.

Transl Oncol. 2024 Oct;48:102071. doi: 10.1016/j.tranon.2024.102071. Epub 2024 Aug 3.

Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment.

Mol Cancer. 2023 Feb 21;22(1):38. doi: 10.1186/s12943-023-01748-4.

Recent Perspectives on the Mechanism of Recurrence After Ablation of Hepatocellular Carcinoma: A Mini-Review.

Front Oncol. 2022 Aug 23;12:895678. doi: 10.3389/fonc.2022.895678. eCollection 2022.

SHR6390 Combined with Cabozantinib Inhibits Tumor Progression in the Hepatocellular Carcinoma Mouse Model.

Curr Gene Ther. 2024;24(5):453-464. doi: 10.2174/1566523222666220825110147.

Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis.

Front Oncol. 2022 Jun 23;12:877434. doi: 10.3389/fonc.2022.877434. eCollection 2022.

Drug delivery strategy in hepatocellular carcinoma therapy.

Cell Commun Signal. 2022 Mar 5;20(1):26. doi: 10.1186/s12964-021-00796-x.

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges.

Front Oncol. 2021 Oct 22;11:737497. doi: 10.3389/fonc.2021.737497. eCollection 2021.

Apatinib suppresses the migration, invasion and angiogenesis of hepatocellular carcinoma cells by blocking VEGF and PI3K/AKT signaling pathways.

Mol Med Rep. 2021 Jun;23(6). doi: 10.3892/mmr.2021.12068. Epub 2021 Apr 13.

Combined immunotherapy and VEGF-antagonist in hepatocellular carcinoma: a step forward.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Combined immunotherapy and VEGF-antagonist in hepatocellular carcinoma: a step forward.

作者信息

机构信息

出版信息

相似文献

引用本文的文献